These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 35385572)

  • 1. Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.
    Sinha N; Sinha S; Valero C; Schäffer AA; Aldape K; Litchfield K; Chan TA; Morris LGT; Ruppin E
    Cancer Res; 2022 Jun; 82(11):2076-2083. PubMed ID: 35385572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
    Valero C; Lee M; Hoen D; Zehir A; Berger MF; Seshan VE; Chan TA; Morris LGT
    JAMA Oncol; 2021 May; 7(5):739-743. PubMed ID: 33599686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy.
    Lee M; Samstein RM; Valero C; Chan TA; Morris LGT
    Hum Vaccin Immunother; 2020; 16(1):112-115. PubMed ID: 31361563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of Tumor Mutational Burden as a Biomarker for Response to Immune Checkpoint Inhibition in the VA Population.
    Scobie MR; Zhou KI; Ahmed S; Kelley MJ
    JCO Precis Oncol; 2023 Sep; 7():e2300176. PubMed ID: 38039430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
    Long J; Wang D; Wang A; Chen P; Lin Y; Bian J; Yang X; Zheng M; Zhang H; Zheng Y; Sang X; Zhao H
    Genome Med; 2022 Feb; 14(1):20. PubMed ID: 35197093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.
    Aggarwal C; Ben-Shachar R; Gao Y; Hyun SW; Rivers Z; Epstein C; Kaneva K; Sangli C; Nimeiri H; Patel J
    JAMA Netw Open; 2023 May; 6(5):e2311181. PubMed ID: 37129893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
    Florou V; Floudas CS; Maoz A; Naqash AR; Norton C; Tan AC; Sokol ES; Frampton G; Soares HP; Puri S; Swami U; Wilky B; Hosein P; Trent J; Lopes GL; Park W; Garrido-Laguna I
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
    Chen Y; Li Y; Guan Y; Huang Y; Lin J; Chen L; Li J; Chen G; Pan LK; Xia X; Xu N; Chang L; Guo Z; Pan J; Yi X; Chen C
    Mol Oncol; 2020 Sep; 14(9):2096-2110. PubMed ID: 32502294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer.
    Liu L; Bai X; Wang J; Tang XR; Wu DH; Du SS; Du XJ; Zhang YW; Zhu HB; Fang Y; Guo ZQ; Zeng Q; Guo XJ; Liu Z; Dong ZY
    Clin Cancer Res; 2019 Dec; 25(24):7413-7423. PubMed ID: 31515453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
    Zhu Y; Yan C; Wang X; Xu Z; Lv J; Xu X; Yu W; Zhou M; Yue L
    Cancer Biol Ther; 2022 Dec; 23(1):104-111. PubMed ID: 35239432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.
    Bortolomeazzi M; Keddar MR; Montorsi L; Acha-Sagredo A; Benedetti L; Temelkovski D; Choi S; Petrov N; Todd K; Wai P; Kohl J; Denner T; Nye E; Goldstone R; Ward S; Wilson GA; Al Bakir M; Swanton C; John S; Miles J; Larijani B; Kunene V; Fontana E; Arkenau HT; Parker PJ; Rodriguez-Justo M; Shiu KK; Spencer J; Ciccarelli FD
    Gastroenterology; 2021 Oct; 161(4):1179-1193. PubMed ID: 34197832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
    Nassar AH; Adib E; Abou Alaiwi S; El Zarif T; Groha S; Akl EW; Nuzzo PV; Mouhieddine TH; Perea-Chamblee T; Taraszka K; El-Khoury H; Labban M; Fong C; Arora KS; Labaki C; Xu W; Sonpavde G; Haddad RI; Mouw KW; Giannakis M; Hodi FS; Zaitlen N; Schoenfeld AJ; Schultz N; Berger MF; MacConaill LE; Ananda G; Kwiatkowski DJ; Choueiri TK; Schrag D; Carrot-Zhang J; Gusev A
    Cancer Cell; 2022 Oct; 40(10):1161-1172.e5. PubMed ID: 36179682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Kao C; Powers E; Wu Y; Datto MB; Green MF; Strickler JH; Ready NE; Zhang T; Clarke JM
    Clin Lung Cancer; 2021 Nov; 22(6):500-509. PubMed ID: 33972172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.
    Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR
    Front Oncol; 2023; 13():1235902. PubMed ID: 37637072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
    Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
    Zheng M
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
    Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
    JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.